Fig. 1From: Proceedings of the 2018 Childhood Arthritis and Rheumatology Research Alliance (CARRA) Scientific Meeting(abstract P2). JDM subject responded well to rituximab therapy who had evidence of oligoclonal B cell expansion and good B cell depletion based on the JC: KRECs ratioBack to article page